{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:05:45Z","timestamp":1755907545719,"version":"3.44.0"},"publisher-location":"New York, NY, USA","reference-count":33,"publisher":"ACM","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,13]]},"DOI":"10.1145\/3570773.3570807","type":"proceedings-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T15:57:42Z","timestamp":1670601462000},"page":"355-359","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Discussions of Chemical, Biological, and Economic Features of two FDA Authorized Antivirals Against COVID-19: Molnupiravir and Paxlovid"],"prefix":"10.1145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-664X","authenticated-orcid":false,"given":"Jiaqian","family":"Dong","sequence":"first","affiliation":[{"name":"Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom"}]}],"member":"320","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"volume-title":"N., Babuadze, G. G., Wong, G. & Kobinger, G. P. Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern. Microorganisms 9, 926","year":"2021","key":"e_1_3_2_1_1_1","unstructured":"COVID-19: epidemiology, virology and clinical features. GOV.UK https:\/\/www.gov.uk\/government\/publications\/wuhan-novel-coronavirus-background-information\/wuhan-novel-coronavirus-epidemiology-virology-and-clinical-features.Shahhosseini, N., Babuadze, G. G., Wong, G. & Kobinger, G. P. Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern. Microorganisms 9, 926, 2021."},{"key":"e_1_3_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0695-z"},{"key":"e_1_3_2_1_3_1","unstructured":"York J. P. in B. Drew Hinshaw in Warsaw and Betsy McKay in New. In Hunt for Covid-19 Origin Patient Zero Points to Second Wuhan Market. WSJ https:\/\/www.wsj.com\/articles\/in-hunt-for-covid-19-origin-patient-zero-points-to-second-wuhan-market-11614335404. 2022"},{"key":"e_1_3_2_1_4_1","doi-asserted-by":"crossref","unstructured":"Zhang Q. Xiang R. Huo S. Zhou Y. Jiang S. & Wang Q. 2021. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy | Signal Transduction and Targeted Therapy. https:\/\/www.nature.com\/articles\/s41392-021-00653-w.","DOI":"10.1038\/s41392-021-00653-w"},{"key":"e_1_3_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.05.002"},{"key":"e_1_3_2_1_6_1","doi-asserted-by":"crossref","unstructured":"Wu Z. & McGoogan J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72\u202f314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323 1239\u20131242 2020.","DOI":"10.1001\/jama.2020.2648"},{"key":"e_1_3_2_1_7_1","volume-title":"https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/1april","author":"Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics.","year":"2021","unstructured":"Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/1april. 2021."},{"key":"e_1_3_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-6976"},{"key":"e_1_3_2_1_9_1","unstructured":"COVID-19 Map.. Johns Hopkins Coronavirus Resource Center. https:\/\/coronavirus.jhu.edu\/map.html. 2022"},{"key":"e_1_3_2_1_10_1","unstructured":"COVID Evaluation Model Estimates 57 Percent of World Population Infected at Least Once. https:\/\/www.msn.com\/en-us\/health\/medical\/covid-evaluation-model-estimates-57-percent-of-world-population-infected-at-least-once\/ar-AAT6yyz. 2022"},{"key":"e_1_3_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2918-0"},{"key":"e_1_3_2_1_12_1","volume-title":"Tourism Policy Responses to the Coronavirus (COVID-19)","author":"Library O.","year":"2020","unstructured":"iLibrary, O. Tourism Policy Responses to the Coronavirus (COVID-19). 2020."},{"key":"e_1_3_2_1_13_1","volume-title":"Developing Economies. https:\/\/www.worldbank.org\/en\/news\/press-release\/2022\/01\/11\/global-recovery-economics-debt-commodity-inequality.","author":"Global Growth","year":"2022","unstructured":"Global Growth to Slow through 2023, Adding to Risk of \u2018Hard Landing\u2019 in Developing Economies. https:\/\/www.worldbank.org\/en\/news\/press-release\/2022\/01\/11\/global-recovery-economics-debt-commodity-inequality. 2022."},{"key":"e_1_3_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2980"},{"key":"e_1_3_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00202-8"},{"key":"e_1_3_2_1_16_1","doi-asserted-by":"crossref","unstructured":"An emerging antiviral takes aim at COVID-19. Chemical & Engineering News https:\/\/cen.acs.org\/pharmaceuticals\/drug-development\/emerging-antiviral-takes-aim-COVID-19\/98\/web\/2020\/05. 2020.","DOI":"10.1021\/cen-09820-feature2"},{"key":"e_1_3_2_1_17_1","unstructured":"Commissioner O. of the. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain 2021."},{"key":"e_1_3_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-021-02841-3"},{"key":"e_1_3_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00651-0"},{"key":"e_1_3_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00657-8"},{"key":"e_1_3_2_1_21_1","volume-title":"English: Chemical structure diagram for Pfizer drug tradename Paxclovid. Uses wedged bond to indicate stereochemistry, for clarity","author":"Turnbull M. D.","year":"2021","unstructured":"Turnbull, M. D. English: Chemical structure diagram for Pfizer drug tradename Paxclovid. Uses wedged bond to indicate stereochemistry, for clarity. 2021."},{"key":"e_1_3_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01063"},{"key":"e_1_3_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2004.06.018"},{"key":"e_1_3_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21475"},{"key":"e_1_3_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127377"},{"key":"e_1_3_2_1_26_1","unstructured":"Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIOTM (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo. Merck.com https:\/\/www.merck.com\/news\/merck-and-ridgeback-to-present-data-demonstrating-that-treatment-with-lagevrio-molnupiravir-was-associated-with-more-rapid-elimination-of-infectious-sars-cov-2-than-placebo\/. 2022."},{"key":"e_1_3_2_1_27_1","unstructured":"Pfizer Announces Additional Phase 2\/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-additional-phase-23-study-results. 2021"},{"key":"e_1_3_2_1_28_1","volume-title":"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study","author":"Pfizer Shares Top-Line EPIC-PEP","year":"2022","unstructured":"Pfizer Shares Top-Line Results from Phase 2\/3 EPIC-PEP Study of PAXLOVIDTM for Post-Exposure Prophylactic Use | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study. 2022."},{"key":"e_1_3_2_1_29_1","volume-title":"Emergency Use Authorization. FDA","author":"Commission","year":"2022","unstructured":"Commissioner, O. of the. Emergency Use Authorization. FDA, 2022."},{"key":"e_1_3_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2034936"},{"key":"e_1_3_2_1_31_1","volume-title":"https:\/\/www.ticksignals.com\/NewsByIndustry\/biotechnology?page=%2FIndex","author":"News By Industry","year":"2022","unstructured":"News By Industry. https:\/\/www.ticksignals.com\/NewsByIndustry\/biotechnology?page=%2FIndex. 2022."},{"key":"e_1_3_2_1_32_1","volume-title":"Pfizer says. CNBC https:\/\/www.cnbc.com\/2022\/05\/03\/pfizer-paxlovid-prescriptions-to-treat-covid-increased-tenfold-in-us-since-late-february.html","author":"Kimball S.","year":"2022","unstructured":"Kimball, S. Paxlovid prescriptions to treat Covid increased tenfold in U.S. since late February, Pfizer says. CNBC https:\/\/www.cnbc.com\/2022\/05\/03\/pfizer-paxlovid-prescriptions-to-treat-covid-increased-tenfold-in-us-since-late-february.html, 2022."},{"key":"e_1_3_2_1_33_1","volume-title":"Molnupiravir Heavily Used Despite Concerns","author":"Kristina Fiore","year":"2022","unstructured":"Kristina Fiore, Molnupiravir Heavily Used Despite Concerns; \u2018Tranq Dope\u2019 Use Rising in U.S. | MedPage Today. https:\/\/www.medpagetoday.com\/special-reports\/exclusives\/97691. 2022."}],"event":{"name":"ISAIMS 2022: 2022 3rd International Symposium on Artificial Intelligence for Medicine Sciences","acronym":"ISAIMS 2022","location":"Amsterdam Netherlands"},"container-title":["Proceedings of the 3rd International Symposium on Artificial Intelligence for Medicine Sciences"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3570773.3570807","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3570773.3570807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:51:29Z","timestamp":1755845489000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3570773.3570807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":33,"alternative-id":["10.1145\/3570773.3570807","10.1145\/3570773"],"URL":"https:\/\/doi.org\/10.1145\/3570773.3570807","relation":{},"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"2022-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}